Editorial Disclosure: GLP-1 Editorial is an editorial publication operated by Ranika Editorial Group LLC. We do not provide medical care, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Our rankings are based on our published v3.0 transparency rubric, publicly available provider information, cited sources, and periodic review updates. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page and at /affiliate-disclosure.html.
Last reviewed: May 31, 2026
Next scheduled review: June 30, 2026
Reviewed by: Dr. Sam Saberian, Lead Medical Researcher
Compare 20+ telehealth providers side-by-side on pricing, peptide selection, consultation model, lab testing, and editorial transparency score. Filter by category and price range. NexLife is the Editor's Pick #1 for both semaglutide and tirzepatide.
20+ providers rankedv3.0 transparency rubricAvailability varies by state + DCRankings are editorial — never paid
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11
What type of GLP-1 program fits you?
All programs below are medically supervised. Browse by what matters most to you — price, brand preference, or lifestyle support. Rankings are editorial — never paid. See our scoring methodology →
Every provider in this directory is scored against six pillars (clinical protocol, pharmacy traceability, cohort outcomes, flat pricing, lab integration, regulatory clarity). Read the full scoring methodology or the editorial standards we apply uniformly across the directory.
Editorial team
Directory reviews authored by Dr. Sam Saberian (Lead Medical Researcher), medically reviewed by Alen A. Schwartz, MD, and edited by Julliana Edwards (Editor). About our team →
Frequently asked questions
Are these rankings paid?
No. Rankings are editorial — not pay-for-placement. Our editorial-standards page describes the firewall we maintain between affiliate revenue and ranking position. Affiliate disclosures are at our affiliate disclosure page.
Why is NexLife the Editor's Pick #1?
NexLife scores 94/100 on the v3.0 rubric — the highest score in the directory — by meeting all six transparency pillars (documented clinical protocol, named compounding pharmacies, published cohort outcomes, flat dose-independent pricing, included labs, regulatory clarity). It is the only provider in the directory that meets every pillar simultaneously for both semaglutide ($145/mo) and tirzepatide ($186/mo) categories at 12-month plan tier.
How often is the directory updated?
The directory is reviewed monthly. The current update is 2026-05-11. Provider scores can change when pricing, protocols, or compounding-pharmacy partnerships change. Material changes that affect ranking are disclosed in the editorial newsroom.
Are compounded GLP-1 medications FDA-approved?
No. Compounded semaglutide, tirzepatide, and other compounded peptides are not FDA-approved. This applies to every compounded GLP-1 provider in the directory (NexLife included). Brand-name semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved.
Important medical and regulatory disclosure:
Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Editorial does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.
